secwatch.observer — SEC 8-K summary
======================================

Issuer:     BullFrog AI Holdings, Inc. (BFRG)
CIK:        0001829247
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001493152-24-040526
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bullfrog AI publishes Cell Reports data supporting BF-114 for liver diseases; adds Dr. Lopa Mishra to advisory board
--------------------------------------------------------------------------------

- Study led by Dr. Lopa Mishra published in Cell Reports provides mechanistic evidence for BF-114 target β2-spectrin (SPTBN1 siRNA) in obesity, MASLD, MASH, and HCC.
- Findings show reducing β2-spectrin can halt progression of MASLD and MASH and reduce liver damage in animal models.
- Dr. Lopa Mishra, a globally recognized liver disease expert, joined Bullfrog AI's Scientific Advisory Board to guide BF-114 development.
- Bullfrog AI will use its bfLEAP AI platform to analyze single-cell data from animal models and human patients for further mechanistic insights.
- BF-114 is an siRNA targeting SPTBN1, aimed at treating obesity-related liver diseases with high unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829247/000149315224040526/0001493152-24-040526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829247/000149315224040526/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer